[en] BACKGROUND: Anti-tumor necrosis factor (TNF) therapy has become a standard therapy for severe inflammatory bowel diseases (IBD), but its effect on B lymphocytes is largely unexplored. In this study we investigated peripheral blood B cells, B-cell subsets, and CD40 expression in patients with IBD before and during anti-TNF therapy with infliximab (IFX). METHODS: Blood was taken from healthy controls (n = 52) and patients with active IBD before (n = 46) and/or during anti-TNF therapy (n = 55). B-cell markers were detected by immunofluorescent staining and FACS analysis. Patients were classified as responders or nonresponders to anti-TNF therapy. RESULTS: We found a numerical deficiency of circulating CD19 B cells, a lower activation state (CD40 expression) and lower proportions of CD5 B cells and IgMIgDCD27 preswitched memory cells among B cells in active patients with IBD before IFX therapy compared with healthy controls. IFX treatment increased CD19 B-cell numbers as well as the proportions of named B-cell subsets in responders but not in nonresponders. IFX more effectively upregulated CD40 expression in responders than in nonresponders. Restoration of B cells correlated with the biological response to therapy (C-reactive protein). Trough serum levels of IFX correlated with the number of B cells during therapy. CONCLUSIONS: A lower number of circulating B cells, a low CD40 expression, and a decrease in the proportion of CD5 and in the preswitched memory subset characterize active IBD. Restoration of these abnormalities correlates with the clinical response to anti-TNF therapy. The mechanism for this effect on B cells should be further explored.
Disciplines :
Life sciences: Multidisciplinary, general & others
Author, co-author :
Li, Zhe
Vermeire, Severine
Bullens, Dominique
Ferrante, Marc
Van Steen, Kristel ; Université de Liège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Noman, Maja
Bossuyt, Xavier
Rutgeerts, Paul
Ceuppens, Jan L.
Van Assche, Gert
Language :
English
Title :
Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.
Publication date :
2015
Journal title :
Inflammatory Bowel Diseases
ISSN :
1078-0998
eISSN :
1536-4844
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Mizoguchi E, Mizoguchi A, Preffer FI, et al. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000;12:597-605.
Croft M, Joseph SB, Miner KT. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. J Immunol. 1997;159:3257-3265.
Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med. 1992;175: 131-138.
Shah S, Qiao L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol. 2008;38:2488-2498.
Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood. 2007;110:2537-2544.
Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006; 176:705-710.
Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or "memory B" cells? J Immunol. 2007;179:13-19.
Bjorck P, Axelsson B, Paulie S. Expression of CD40 and CD43 during activation of human B lymphocytes. Scand J Immunol. 1991;33: 211-218.
Chong Y, Ikematsu H, Yamaji K, et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol. 2005;17:383-390.
Wehr C, Eibel H, Masilamani M, et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol. 2004;113: 161-171.
Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009;11:R84.
Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med. 1959;110:657-674.
Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. JAutoimmun. 2000;14:83-97.
Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
Sattler S, Ling GS, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 2014;50:107-122.
Neil GA, Summers RW, Cheyne BA, et al. CD5+ B cells are decreased in peripheral blood of patients with Crohn's disease. Dig Dis Sci. 1992;37: 1390-1395.
Di Sabatino A, Carsetti R, Rosado MM, et al. Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004;8:199-203.
Yacyshyn BR, Pilarski LM. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. Gut. 1993;34:1698-1704.
Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology. 1995;108:132-137.
Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. JLeukoc Biol. 2009;86:1007-1016.
Ferkolj I, Ihan A, Markovic S. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease. Hepatogastroenterology. 2005; 52:1128-1133.
Lichtenstein GR. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Curr Opin Gastroenterol. 2000;16:83-88.
Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990;86:1255-1260.
van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis. 1999;58(suppl 1):I114-I120.
Karampetsou MP, Andonopoulos AP, Liossis SN. Treatment with TNFal-pha blockers induces phenotypical and functional aberrations in peripheral B cells. Clin Immunol. 2011;140:8-17.
Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-1043.
Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. In-flamm Bowel Dis. 2008;14:591-596.
Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010;16:1299-1310.
Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152-172.
Fu L, Lin-Lee YC, Pham LV, et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006;107:4540-4548.
Pham LV, Tamayo AT, Yoshimura LC, et al. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106:3940-3947.
Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999;163:4049-4057.
Mishima Y, Ishihara S, Amano Y, et al. Alterations of peripheral blood CD5+ B cells in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:172-179.
Pers JO, Jamin C, Predine-Hug F, et al. The role of CD5-expressing B cells in health and disease (review). Int J Mol Med. 1999;3:239-245.
Bohm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother. 2004;58:338-343.
van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131:1204-1212.
Lee JH, Noh J, Noh G, et al. IL-10 is predominantly produced by CD19 (low)CD5(+) regulatory B cell subpopulation: characterisation of CD19 (high) and CD19(low) subpopulations of CD5(+) B cells. Yonsei Med J. 2011;52:851-855.
Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2002;46:2160-2171.
